Rapid increase of serum neuron specific enolase level and tachyphylaxis of EGFR-tyrosine kinase inhibitor indicate small cell lung cancer transformation from EGFR positive lung adenocarcinoma?

Kinase Inhibitor ◽

Neuron Specific Enolase ◽

Small Cell ◽

Small Cell Lung ◽

Serum Neuron Specific Enolase

Egfr-Tyrosine Kinase Inhibitor (Tki) Rechallenge with Bevacizumab in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc)

Annals of Oncology ◽

10.1093/annonc/mdu349.65 ◽

2014 ◽

Vol 25 ◽

pp. iv452

Author(s):

K. Otsuka ◽

A. Hata ◽

R. Kato ◽

J. Takeshita ◽

C. Okuda ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

Egfr Mutant

Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

BMC Cancer ◽

10.1186/1471-2407-11-1 ◽

2011 ◽

Vol 11 (1) ◽

Cited By ~ 81

Author(s):

Satoshi Watanabe ◽

Junta Tanaka ◽

Takeshi Ota ◽

Rie Kondo ◽

Hiroshi Tanaka ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

Lung Cancer Patients ◽

Clinical Responses

Calpain4 Regulates The Response Of Non-Small Cell Lung Cancer Cell Lines To EGFR Tyrosine Kinase Inhibitor Erlotinib

10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a6288 ◽

2012 ◽

Author(s):

Sucheta Kulkarni ◽

Leya Saju ◽

Carol F. Farver

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Cell Lines ◽

Kinase Inhibitor ◽

Small Cell ◽

Lung Cancer Cell ◽

Small Cell Lung ◽

CLINICAL ANALYSIS OF AFATINIB IN EGFR-TYROSINE KINASE INHIBITOR NAÏVE PATIENTS WITH NON-SMALL CELL LUNG CANCER HABORING EGFR MUTATIONS

Respirology ◽

10.1111/resp.13207_77 ◽

2017 ◽

Vol 22 ◽

pp. 114-114 ◽

Cited By ~ 1

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Kinase Inhibitor ◽

Clinical Analysis ◽

Small Cell ◽

Egfr Mutations ◽

Small Cell Lung ◽

Abstract 3802: Effect of CS-7017, a selective PPARδ agonist, on the TGFβ/Smad-mediated enhanced cell motility of EGFR-tyrosine kinase inhibitor-resistant non-small cell lung cancer cells

10.1158/1538-7445.am2012-3802 ◽

2012 ◽

Author(s):

Masakuni Serizawa ◽

Masaru Watanabe ◽

Junko Suzuki ◽

Akane Naruoka ◽

Haruyasu Murakami ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Cell Motility ◽

Cancer Cells ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

Evaluation of the potential effect of dacomitinib, an EGFR tyrosine kinase inhibitor, on ECG parameters in patients with advanced non-small cell lung cancer

Investigational New Drugs ◽

10.1007/s10637-019-00887-0 ◽

2019 ◽

Vol 38 (3) ◽

pp. 874-884

Author(s):

Weiwei Tan ◽

Nagdeep Giri ◽

Susan Quinn ◽

Keith Wilner ◽

Kourosh Parivar

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Potential Effect ◽

Small Cell ◽

Small Cell Lung ◽

Spatiotemporal T790M heterogeneity in individual patients with non-small cell lung cancer (NSCLC) after acquired resistance to EGFR-tyrosine kinase inhibitor (TKI).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.8067 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 8067-8067 ◽

Cited By ~ 1

Author(s):

Akito Hata ◽

Nobuyuki Katakami ◽

Hiroshige Yoshioka ◽

Katsuhiro Masago ◽

Shiro Fujita ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Small Cell ◽

Small Cell Lung ◽

A single-arm phase II study of afatinib treatment for advanced EGFR-mutant non-small cell lung cancer (mNSCLC) patients (pts) with EGFR-tyrosine kinase inhibitor (TKI) resistance.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e19031 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e19031-e19031 ◽

Cited By ~ 2

Author(s):

Jair Bar ◽

Dana Botser ◽

Rossie Navon ◽

Nir Peled ◽

Haim Biran ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Kinase Inhibitor ◽

Phase Ii Study ◽

Small Cell ◽

Small Cell Lung ◽

Tki Resistance ◽

Egfr Mutant

BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation

British Journal of Cancer ◽

10.1038/sj.bjc.6605748 ◽

2010 ◽

Vol 103 (3) ◽

pp. 347-353 ◽

Cited By ~ 17

Author(s):

Y Loriot ◽

P Mordant ◽

N Dorvault ◽

T De la motte Rouge ◽

J Bourhis ◽

...

Keyword(s):

Lung Cancer ◽

Synergistic Effect ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

9087 POSTER Clinical Responses to EGFR-tyrosine Kinase Inhibitor Retreatment in Non-small Cell Lung Cancer Patients Who Benefited Prior Gefitinib Therapy

European Journal of Cancer ◽

10.1016/s0959-8049(11)72399-1 ◽

2011 ◽

Vol 47 ◽

pp. S618-S619

Author(s):

S. Watanabe ◽

Y. Saida ◽

K. Ichikawa ◽

J. Koshio ◽

J. Baba ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

Lung Cancer Patients ◽

Clinical Responses